scholarly journals Minireview: Thyrotropin-Releasing Hormone and the Thyroid Hormone Feedback Mechanism

2009 ◽  
Vol 94 (4) ◽  
pp. 1472-1472
Author(s):  
Maria Izabel Chiamolera ◽  
Fredric E. Wondisford
2004 ◽  
Vol 18 (7) ◽  
pp. 1708-1720 ◽  
Author(s):  
S. Ishii ◽  
M. Yamada ◽  
T. Satoh ◽  
T. Monden ◽  
K. Hashimoto ◽  
...  

1992 ◽  
Vol 184 (1) ◽  
pp. 367-372 ◽  
Author(s):  
Masanobu Yamada ◽  
Tuyoshi Monden ◽  
Teturou Satoh ◽  
Masahiko Iizuka ◽  
Masami Murakami ◽  
...  

PEDIATRICS ◽  
1986 ◽  
Vol 78 (6) ◽  
pp. 1114-1122
Author(s):  
Nancy J. Hopwood ◽  
Sue Ellyn Sauder ◽  
Brahm Shapiro ◽  
James C. Sisson

The diagnosis of partial peripheral and pituitary resistance to thyroid hormone was ultimately made in two boys, 7 and 9 years of age, and a 10-year-old girl who had goiters and hyperthyroxinemia. The boys were treated with propythiouracil and/or thyroidectomy or iodine 131 for suspected thyrotoxicosis but had poorly suppressible serum thyroid-stimulating hormone (TSH) post treatment in spite of the usual L-thyroxine replacement. The girl had increasing goiter size while receiving propylthiouracil, 100 mg every eight hours. These findings led to reevaluation of thyroid hormone dynamics in these children and their families. Twelve additional family members, 3 to 38 years of age, compatible with an autosomal dominant inheritance, were also found to have peripheral and pituitary resistance to thyroid hormone. All affected individuals had elevated serum thyroxine and triiodothyronine levels, normal to slightly elevated triiodothyronine resin uptakes, and a nonsuppressed serum TSH. The five individuals who were given thyrotropin-releasing hormone showed exaggerated TSH responses, which normalized on L-thyroxine therapy. Misdiagnosis in six of 15 family members led to significant morbidity (hypothyroidism, delayed growth, and therapy risk). A nonsuppressed serum TSH in a patient with suspected thyrotoxicosis should lead to suspicion of this disorder. Appropriate management for this condition includes L-thyroxine therapy to decrease goiter size and normalize TSH responses to thyrotropin-releasing hormone.


Sign in / Sign up

Export Citation Format

Share Document